Taking a Breather: Advances in Interleukin 5 Inhibition for Asthma Relief

Massey, Oliver; Suphioglu, Cenk

doi:10.3390/ijms231911166

Cited by 3 publications

(2 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Benralizumab ya ha sido aprobado para tratar el asma eosinofílica en adolescentes y adultos. 59 Un ensayo fase 3 recién finalizado (no publicado aún) ha demostrado la superioridad de benralizumab frente a placebo para inducir la remisión histológica de la EoE; sin embargo, no se pudo demostrar que este fármaco resultara superior al placebo para controlar los síntomas. Finalmente, tezepelumab, un anticuerpo dirigido a la linfopoyetina estromal tímica, evaluado y aprobado como co-terapia en asma bronquial de difícil control, será evaluado próximamente en la EoE.…”

Section: Fármacos Biológicosunclassified

Novedades terapéuticas en la esofagitis eosinofílica

Molina–Infante

Lucendo

2022

ACTA

View full text Add to dashboard Cite

La esofagitis eosinofílica (EoE) es una enfermedad inmunoalérgica crónica causada, en la mayoría de los casos, por una alergia alimentaria no IgE mediada. Su prevalencia actual es superior a 1 caso por cada 1000 habitantes en España y Europa, mientras que es emergente en el continente sudamericano. Esta revisión trata de actualizar las novedades terapéuticas aparecidas en los últimos 5 años para inducción y mantenimiento en esta patología, incluyendo la aparición de nuevos fármacos antiácidos (inhibidores del ácido competitivos del potasio), la simplificación de los esquemas dietéticos, la aparición de nuevos corticoides deglutidos diseñados específicamente para el tratamiento tópico, así como la incorporación de fármacos biológicos al algoritmo terapéutico de la enfermedad. La dilatación endoscópica continúa siendo un complemento eficaz y seguro para la mejoría sintomática, en combinación con tratamientos antiinflamatorios de la enfermedad.

show abstract

Section: Fármacos Biológicosunclassified

Novedades terapéuticas en la esofagitis eosinofílica

Molina–Infante

Lucendo

2022

ACTA

View full text Add to dashboard Cite

show abstract

“…Because of the crucial role that it plays for eosinophils (from eosinophilopoiesis to their activation), IL-5 has been identified a therapeutic target for eosinophilic disorders, and its pathway can be antagonized by several biological agents (mepolizumab, benralizumab, and reslizumab, already licensed, and depemokimab, under investigations) (Fig. 2 ) [ 3 ]. Mepolizumab, a humanized IgG1-κ monoclonal antibody, binds to IL-5, preventing its interaction with the IL-5 receptor, hence inhibiting its cascade [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan

Lombardi,

Comberiati,

Ridolo

et al. 2024

Drugs

View full text Add to dashboard Cite

Monoclonal antibodies targeting interleukin (IL)-5 pathways have revolutionized the treatment expectations for eosinophilic-associated conditions, particularly in patients with respiratory involvement. Mepolizumab (IL-5 antagonist monoclonal antibody), benralizumab (IL-5 receptor blocker monoclonal antibody), and reslizumab (IL-5 antagonist monoclonal antibody) have collectively contributed to the overall improvement of the disease burden in various conditions. Eosinophilic asthma currently boasts the most robust evidence across all age groups: all three biologics are approved for adults (aged ≥18 years); mepolizumab is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) also in children (aged ≥ 6 years), while bernalizumab was recently approved by the FDA for patients aged ≥6 years in the USA. In chronic rhinosinusitis with nasal polyps, subcutaneous mepolizumab is the only anti-IL-5 therapy approved so far and can be used in adult patients (aged ≥18 years). For eosinophilic esophagitis, conflicting evidence surrounds both mepolizumab, reslizumab, and benralizumab, leading to non-approval of these agents by the FDA/EMA. Recently, mepolizumab was approved for eosinophilic granulomatosis with polyangiitis patients aged ≥6 years or older and for hypereosinophilic syndrome adult patients. A phase III trial proving noninferiority of benralizumab versus mepolizumab in eosinophilic granulomatosis with polyangiitis has been recently published, while evidence on reslizumab is scant. Overall, current evidence on anti-IL-5 biologics for eosinophilic-associated disorders is mostly focused on adults, whereas data for individuals aged under 18 years and over 65 years are scarce, resulting in a lack of evidence, particularly regarding efficacy, for the use of anti-IL-5 agents in these specific patient populations. This review addresses high-quality evidence from randomized controlled trials and real-world post-marketing studies regarding the use of anti-IL-5 therapies for eosinophilic-associated disorders across all age groups, spanning childhood, adulthood, and older age.

show abstract